We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Blood Testing Method Detects Potent Opioids in Under Three Minutes

By LabMedica International staff writers
Posted on 26 Feb 2024

Fentanyl, an opioid 50 times more potent than heroin, presents a major risk to public health. More...

In recent years, there's been a growing concern over the rise in fentanyl use among drug users. Annually, this potent drug is responsible for thousands of overdose deaths globally. In response to this crisis, a breakthrough in drug testing has been achieved. Now, researchers have developed a new blood testing method capable of detecting powerful opioids, including fentanyl, more rapidly than traditional methods, thereby offering a potential lifeline in overdose situations.

This innovative method developed by a team at the University of Waterloo (Ontario, Canada) can simultaneously analyze up to 96 blood samples for the presence of opioids like fentanyl in less than three minutes, a rate that's double the speed of existing methods. To conduct the test, a small volume of blood is placed into each well of a 96-well plate, which also contains a phosphate buffer. This plate is then inserted into a device that shakes the samples. Next, a solid phase microextraction (SPME) probe is used to target and extract the drugs of interest. The final step involves analyzing the sample with a mass spectrometer connected to a microfluidic open interface. Impressively, this process yields results in approximately 90 seconds.

"The difference between our blood testing method and traditional methods used in laboratories and hospitals is that we can do it faster and reach the same conclusion," said Emir Nazdrajić, a postdoctoral fellow in Waterloo's Department of Chemistry. "Let's say someone who has overdosed is in the emergency room, and doctors need to quickly determine what they've taken to treat them effectively. The speed of our method can be lifesaving."

"There is a high demand for rapid screening methods using mass spectrometry (MS) that can decrease the turnaround time, cost, and limits of quantitation of existing methodologies," added Dr. Janusz Pawliszyn, a professor in Waterloo's Department of Chemistry. "Our method targets not only fentanyl but other drugs and certain types of diseases."

Related Links:
University of Waterloo


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.